Share on LinkedInShare on LinkedIn

ARTICLE · 03 JULY 2026

Artificial Intelligence, Privilege, And Work Product: Emerging Risks In The Life Sciences Industry

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

Recent court decisions reveal conflicting approaches to whether communications with generative AI tools waive attorney-client privilege or work product protection, creating significant uncertainty for companies handling sensitive legal and proprietary information. Life sciences companies face heightened risks as they increasingly rely on AI tools while managing confidential clinical data, regulatory strategies, and intellectual property that may become subject to discovery in future litigation.

United StatesCorporate/Commercial Law

Introduction

As artificial intelligence (AI) use has become prevalent in nearly every stage of litigation, including pre-litigation efforts, courts and litigants alike have encountered challenges applying longstanding doctrine to new technology. Recent decisions indicate that courts disagree on whether communications with generative AI tools are more like disclosures to a third party or more like the use of traditional word-processing tools. In particular, courts are grappling with whether disclosure of sensitive information to publicly available AI platforms constitutes disclosure to a “third party” sufficient to waive attorney-client privilege or undermine attorney work-product protection.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from